We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+34.6%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$555M
AUM Growth
-$203M
Cap. Flow
-$287M
Cap. Flow %
-51.67%
Top 10 Hldgs %
64.54%
Holding
90
New
25
Increased
22
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
THER
THERATECHNOLOGIES INC COM
THER
+$26.9M
2
KRYS icon
Krystal Biotech
KRYS
+$11.4M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.8M
4
AZN icon
AstraZeneca
AZN
+$9.76M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.78M

Top Sells

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$10.2M
2
VCEL icon
Vericel Corp
VCEL
+$7.3M
3
EPIX
ESSA Pharma
EPIX
+$7.1M
4
MRSN
Mersana Therapeutics
MRSN
+$5.5M
5
DRIO icon
DarioHealth
DRIO
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 90.73%
2 Consumer Staples 1.79%
3 Real Estate 0.62%
4 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HIMS icon
76
Hims & Hers Health
HIMS
$6.87B
– –
-281,565
Closed -$4.11M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
– –
-8,274
Closed -$5.5M
TARA icon
78
Protara Therapeutics
TARA
$230M
– –
-16,093
Closed -$390K
VCEL icon
79
Vericel Corp
VCEL
$2.29B
– –
-236,589
Closed -$7.3M
XBI icon
80
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-2,825,000
Closed -$398M
ZYME icon
81
Zymeworks
ZYME
$1.7B
– –
-22,631
Closed -$1.07M
NVRO
82
DELISTED
NEVRO CORP.
NVRO
– –
-9,589
Closed -$1.66M
NVTA
83
DELISTED
Invitae Corporation
NVTA
– –
-244,760
Closed -$10.2M
MDNA
84
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
– –
-186,799
Closed -$874K
PRVB
85
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-105,941
Closed -$1.79M
OAC.WS
86
DELISTED
Oaktree Acquisition Corp. Warrants, each whole warrant exercisable for one Class A Ordinary Share at
OAC.WS
– –
-91,793
Closed -$358K
HZNP
87
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-12,655
Closed -$926K
BHVN
88
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-7,661
Closed -$657K
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Soleus Capital Management held 90 positions worth $555M, down 27% from $758M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Soleus Capital Management withdrew a net $287M in Q1 2021, closing 18 positions and reducing 13 holdings. Its most notable exit was Invitae Corporation, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 44% a quarter earlier, followed by Consumer Staples and Real Estate.

Against the trend, Soleus Capital Management opened a new position in THERATECHNOLOGIES INC COM worth $26.9M.

  • Soleus Capital Management's largest Q1 2021 buy was THERATECHNOLOGIES INC COM: 6,951,347 shares worth $26.9M.
  • Soleus Capital Management added most to Krystal Biotech in Q1 2021, an estimated $11.4M increase.
  • Soleus Capital Management's biggest Q1 2021 reduction was ESSA Pharma, cutting an estimated $7.1M.
  • Soleus Capital Management fully exited Invitae Corporation in Q1 2021, selling an estimated $10.2M.
  • Soleus Capital Management's ten largest holdings make up 65% of its $555M portfolio in Q1 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q1 2021.
  • Soleus Capital Management's portfolio value fell 27% quarter-over-quarter to $555M.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.